AAPLLoadingMSFTLoadingNVDALoadingGOOGLLoadingAMZNLoadingMETALoadingTSLALoadingAMDLoadingNFLXLoadingCOINLoadingPYPLLoadingSPYLoadingQQQLoadingIWMLoadingJPMLoadingVLoadingDISLoadingKOLoadingJNJLoadingNKELoadingXOMLoadingASMLLoading
FreeADBE4 min read

Seat pricing meets software that needs fewer seats

It last traded at 251.69, +3.11% on the session. I have admired this business for a long time, and the case I want to make against it is about the pricing model rather than the product.

ADBE
Delayed

The problem with counting people

Most professional software is priced per seat: one licence for each person who uses it. That works beautifully while the number of people doing the work keeps growing, because revenue grows with headcount at no extra effort.

It works much less well when the software starts doing some of the work itself. Tools that let one person produce what used to take three are a genuine improvement for the customer. For a vendor paid by the seat, they are a way of selling fewer seats.

Where the pressure shows

  • Seat growth at the largest customers, where procurement notices first
  • The mix between individual and enterprise plans, since enterprises negotiate hard on volume
  • Pricing tied to usage or output, and how quickly it arrives, because it is the obvious answer and it rarely comes without a transition cost
  • New entrants offering cheaper tools to the occasional user the incumbent never priced for

A productivity gain is a price cut, eventually. The only question is who captures it.

Where I stand

Short, and uncomfortably so. The product is excellent and the customer base is loyal. The view is not that the business shrinks. It is that the pricing model has to change, and pricing model changes tend to cost a few quarters of growth that the valuation does not allow for.

What would change my mind

Evidence that usage or output pricing is being adopted without seat erosion. If the transition happens quietly, I will have been wrong about the cost of the change, and the business will have earned its multiple.

The author holds no position in the instruments discussed. Opinion. Not advice. Not a financial promotion approved under FSMA s.21. Quote data is delayed. Past performance is not a reliable indicator of future results.

Comments

0 comments
Sign in to comment.

No comments yet

Be the first to weigh in.